RT Conference Proceedings
T1 MASS CYTOMETRY DATA RECLASSIFY SYSTEMIC AUTOIMMUNE DISEASE PATIENTS IN PHENOTYPICALLY DISTINCTIVE GROUPS
A1 Rybakowska, P.
A1 van Gassen, S.
A1 Perez-Sanchez, C.
A1 Ibanez-Costa, A.
A1 Varela, N.
A1 Castro, R. Ortega
A1 Fernandez-Roldan, C.
A1 Jimenez-Moleon, I.
A1 Ortego, N.
A1 Raya, E.
A1 Quesada, R. Aguilar
A1 Lopez-Pedrera, C.
A1 Estevez, E. Collantes
A1 Saeys, Y.
A1 Alarcon-Riquelme, M.
A1 Maranon, C.
K1 Antiphospholipid syndrome
K1 Mixed connective tissue disease
K1 Undifferentiated connective tissue diseases
K1 Proteomics
AB Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSC), Sjögren’s syndrome (SJS), mixed connective tissue disease (MCTD), primary antiphospholipid syndrome (PAPS) and undifferentiated connective tissue disease (UCTD) are classified as systemic autoimmune diseases (SADs). They are diagnosed based on different clinical and laboratory criteria. Due to their high internal heterogeneity and overlapping symptoms, SADs are difficult to diagnose. Therefore, molecular and cellular-based studies need to be undertaken to precisely classify the patients. Mass cytometry is a single-cell proteomics technology that measures  approximately 50 markers per cell, thus it is a suitable tool to perform deep-phenotyping studies in SADs.
PB BMJ Group
SN 0003-4967
YR 2022
FD 2022-06-01
LK http://hdl.handle.net/10668/20061
UL http://hdl.handle.net/10668/20061
LA en
DS RISalud
RD Apr 6, 2025